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A B S T R A C T
Objectives: The recent PANTAP trial showed that administration of prophylactic antibiotics in locally advanced
head and neck carcinoma (LAHNC) patients treated with chemoradiotherapy reduced fever, hospitalization and
costs. The current study describes the effect of prophylactic antibiotics on health-related quality of life (HRQoL),
another secondary endpoint of the trial.
Materials and methods: In this multicenter randomized trial, LAHNC patients treated with chemoradiotherapy
received prophylactic antibiotics or standard care. HRQoL was assessed at baseline (before chemoradiotherapy),
day 28 of chemoradiotherapy (one day before starting prophylactic antibiotics), the final day of radiotherapy,
and 3.5months after the end of chemoradiotherapy, using the European Organisation for Research and
Treatment of Cancer (EORTC) QLQ-C30, EORTC H&N35 module, and the Performance Status Scale for Head &
Neck cancer patients (PSS-HN).
Results: Ninety-five patients were randomized: 48 patients were allocated to the standard group and 47 patients
to the prophylaxis group. Thirty-four patients in the standard group (70.8%) and 28 patients in the prophylaxis
group (59.6%) completed the questionnaires at baseline and at follow-up. No significant differences in HRQoL
were found at baseline and at day 28. At the end of radiotherapy, the prophylaxis group performed better on
almost all functional subscales of the EORTC QLQ-C30 and reported less symptoms. At the end of follow up,
almost no differences were seen between the two treatment groups.
Conclusion: Prophylactic antibiotics during chemoradiotherapy for LAHNC patients improved HRQoL at the end
of the radiotherapy, however no differences were found 3.5months after the end of chemoradiotherapy.
Introduction
Head and neck cancer is the sixth most common type of cancer with
an annual incidence of 686,328 new cases worldwide [1,2]. Locally
advanced head and neck cancer (LAHNC) itself, as well as the side ef-
fects of treatment, can negatively influence health-related quality of life
(HRQoL). Social and emotional interactions are important aspects of an
individual’s HRQoL and largely depend on structural and functional
capacity of organs in the head and neck region that are affected by the
tumour and its treatment [3]. Rettig et al. showed that HRQoL begins to
decline in the 2–5 years before a diagnosis of LAHNC with a steep re-
duction in the 24months before diagnosis [4]. At presentation, disease-
related symptoms may comprise of hoarseness, pain, otalgia, dysphagia,
cough and stridor [5], which likely to account for decreased HRQoL
prior to diagnosis.
The treatment for LAHNC often consists of concomitant platinum-
based chemoradiotherapy. However, this treatment is associated with a
high rate of acute toxicities. Radiotherapy causes mucositis, dermatitis,
dysphagia, anorexia and pain [6,7], whereas chemotherapy may cause
nausea, neutropenia and thrombocytopenia and worsen radiotherapy-
related toxicities, in particular mucositis and dysphagia [6]. In a pre-
vious study, the incidence of grade 3 or 4 acute toxicities among
LAHNC patients treated with radiotherapy alone was 47%, while this
was 77% among patients treated with concomitant chemoradiotherapy
[6]. Due to these acute adverse events, there is a significant dete-
rioration of HRQoL during treatment [8], that may be worse for
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patients treated with chemoradiotherapy compared to those treated
with radiotherapy alone [9]. Immediately (4–6weeks) after radio-
therapy HRQoL declines even further [10,11], however gradual im-
provement is during the following period [4,9–12]. In general, most
HRQoL domains recover to baseline levels around 12months after
treatment [9,13].
Dysphagia and aspiration during-and after chemoradiotherapy for
head and neck cancer are usually underreported [14–16]. In LAHNC
patients, the incidence of aspiration at diagnosis ranges from 9% to
53% [14,17], and the aspiration rate during and after chemor-
adiotherapy is between 13% and 69% [16–18]. As a consequence, as-
piration pneumonia during chemoradiotherapy is a relatively frequent
complication (46%) [19]. In the recently conducted PANTAP-trial,
prophylactic antibiotics during chemoradiotherapy in LAHNC did not
result in a reduction in the number of patients with a pneumonia
(45.8% of the patients in the standard group versus 46.8% of the pa-
tients in the prophylaxis group), however prophylactic antibiotics led to
a significant reduction in the rate of hospitalization, episodes of fever
and costs per patient [19,20]. It could be hypothesized that prophy-
lactic antibiotics have a protective effect on HRQoL as they may reduce
acute toxicities such as mucositis and pain, which were previously
shown to have a negative impact on HRQoL [21]. One of the secondary
objectives of the PANTAP trial, and the aim of the current study, was to
assess the effects of prophylactic antibiotics during chemoradiotherapy
on the HRQoL among LAHNC patients compared with those who did
not receive prophylactic antibiotics. We hypothesized that the group
receiving prophylactic antibiotics would report a better HRQoL at the
end of radiotherapy due to the positive effects of prophylactic anti-
biotics. In addition, our study aims to describe HRQoL changes during
treatment in both treatment groups.
Methods
Patients and study design
The PANTAP-study was a randomized, multicenter phase II study
for patients with LAHNC who were treated with chemoradiotherapy,
either as primary treatment or postoperative treatment. Chemotherapy
consisted of cisplatin, given at a dose of 100mg/m2 every 3 weeks for 3
cycles, or 40–50mg/m2 given every week for 6 or 7 cycles.
Radiotherapy was given with intensity-modulated radiation therapy
and an accelerated (68 Gy in 34 fractions of 2 Gy over 5.5 weeks) or
conventional scheme (70 Gy in 35 fractions of 2 Gy over 7 weeks) [6,7]
Patients were enrolled before start of the chemoradiotherapy. Exclusion
criteria for registration included an allergy to amoxicillin, the use of
maintenance antibiotics or immunodeficiency. Patients were rando-
mized after 21–28 days of chemoradiotherapy, unless complications
such as pneumonia, other infections or antibiotic treatment had oc-
curred within the 14 days preceding randomization. Patients were
randomized to receive either standard care alone, (the standard group),
or to receive prophylactic oral amoxicillin/clavulanic acid 625mg three
times daily from day 29 until 14 days after the end of chemor-
adiotherapy in addition to standard care (the prophylaxis group). Pa-
tients were allocated equally to the two treatment groups by mini-
mization, which is a method of adaptive stratification allowing a higher
numbers of stratification factors: smoking, Chronic Obstructive Pul-
monary Disease (Gold 0–2 or Gold 3–4), weight loss (more than 10%
versus less than 10%), primary site of the tumour (oral cavity, or-
opharyngeal, or hypopharyngeal and laryngeal cancer), participating
centre, and human papillomavirus positivity [22].
The primary endpoint was to evaluate the number of patients who
developed pneumonia. Secondary endpoints were to determine the
number and duration of hospital admissions, to assess toxicity and
adverse events including side effects of amoxicillin/clavulanic acid, to
evaluate cost-effectiveness, and to explore HRQoL.
The study protocol was approved by the local ethical committee and
registered at http://clinicaltrials.gov (NCT01598402).
Assessments
HRQoL was assessed at baseline, day 28 of chemoradiotherapy (one
day before starting prophylactic antibiotics), on the final day of
radiotherapy, and 3.5 months after the end of chemoradiotherapy.
Questionnaires included the 30-item core European Organization for
the Research and Treatment of Cancer Quality-of-Life Questionnaire
(EORTC QLQ-C30) [23], the EORTC QLQ Head and Neck Cancer-Spe-
cific Module (EORTC H&N35) [23], and the Performance Status Scale
for Head & Neck cancer patients (PSS-HN) [24].
The EORTC QLQ-C30 is a 30-item questionnaire that assesses
HRQoL in cancer patients across five functioning scales (physical
functioning, role functioning, emotional functioning, cognitive func-
tioning, social functioning), three multi-item symptom scales (fatigue,
pain, nausea and vomiting), six single-item symptom scales (dyspnoea,
insomnia, appetite loss, constipation, diarrhoea, and financial pro-
blems) and global QoL [23]. Patients provide their answers on a 4-point
scale (from 1 [not at all] to 4 [very much]), except for global QoL,
which has a 7-point scale (from 1 [very poor] to 7 [excellent]). By
linear transformation the raw scores are standardized, so that overall
scores range from 0 to 100. A higher score on the functioning scales and
on global QoL represent a better level of quality of life and functioning,
and a higher score on the symptom scales means a worse level of
symptoms [25]. According to EORTC Quality of Life Group guidelines,
clinically important differences between the two treatment groups were
divided into four classes based on size: large (representing unequivocal
clinical relevance), medium (likely to be clinically relevant, but to a
lesser extent), small (subtle but, nevertheless, clinically relevant) and
trivial (circumstances unlikely to have any clinical relevance, or where
there was no difference). For each subscale criteria to fit each of the
four classes were composed [26]. Within each treatment group clinical
relevant differences over time were defined as a difference of at least 10
points [27].
The EORTC H&N35, a disease-specific HRQoL questionnaire,
Table 1
Patient characteristics at baseline (no statistically significant differences be-
tween the study groups).
All patients Patients with complete
HRQoL questionnaires
Standard
group
(n= 48)
Prophylaxis
group
(n= 47)
Standard
group
(n= 34)
Prophylaxis
group
(n= 28)
Age-yr (range) 58.5
(43–68)
57.0 (23–68) 58.5
(48–68)
58.1 (29–68)
Sex – no. (%)
Female 14 (29.2) 11 (23.4) 10 (29.4) 7 (25.0)
Male 34 (70.8) 36 (76.6) 24 (70.6) 21 (75.0)
WHO– no. (%)
0 35 (72.9) 32 (68.1) 26 (76.5) 19 (67.9)
1 11 (22.9) 11 (23.4) 7 (20.6) 7 (25.0)
Unknown 2 (4.2) 4 (8.5) 1 (2.9) 2 (7.1)
Tumor site– no. (%)
Oral cavity 14 (29.2) 13 (27.7) 9 (26.5) 6 (21.4)
Oropharynx 20 (41.7) 20 (42.6) 14 (41.2) 14 (50.0)
Hypopharynx 5 (10.4) 11 (23.4) 4 (11.8) 7 (25.0)
Larynx 8 (16.7) 3 (6.4) 7 (20.6) 1 (3.6)
Unknown
primary
1 (2.1) 0 0 0
Indication CRT– no. (%)
Primary
treatment
26 (54.2) 34 (72.3) 19 (55.9) 20 (71.4)
Postoperative
treatment
22 (45.8) 13 (27.7) 15 (44.1) 8 (28.6)
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comprises 35 questions assessing symptoms and side effects of treat-
ment, social function and body image/sexuality, and incorporates seven
multi-item scales (pain, swallowing, senses (taste and smell), speech,
social eating, social contact, sexuality), and 11 single item scales (teeth,
opening mouth, dry mouth, sticky saliva, coughing, felt ill, pain killers,
nutritional supplements, feeding tube, weight loss, weight gain). After
linear transformation, all symptom scales range in score from 0 to 100,
where a higher score means more complaints [23]. A difference of at
least 10 points between the two treatment groups, as well as within the
groups, was considered to be a clinically significant difference [27].
The PSS-HN was designed to measure unique disabilities of head
and neck cancer patients. Surgery and/or systemic therapies in head
and neck cancer patients often introduce cosmetic and functional def-
icits leading to problems with speech and eating [28]. The PSS-HN was
developed as a simple and practical assessment and consists of three
subscales: ‘normalcy of diet’, ‘understandability of speech’, and ‘eating
in public’. Each is rated from 0 to 100, with higher scores indicating
better performance, and 100 representing normal function [24]. The
‘normalcy of diet’ subscale assesses the extent to which the patient is
able to eat a regular diet. The ‘understandability of speech’ subscale
rates the degree to which a listener is able to understand the patient’s
speech. The ‘eating in public’ subscale scores swallowing-related QoL
issues by documenting the patient’s ability to share a meal with others,
and in which type of environment. The PSS-HN has been shown to have
adequate inter-rater reliability and to be sensitive to differences in
performance and change over time [24]. There are no studies per-
formed to determine clinically relevant differences on the three sub-
scales, as with the QLQ-C30 and QLQ-H&N35, however, a score of 50 or
less on the different scales seems to correlate with a lower Karnofsky
performance scale [24]. Norman’s rule of thumb was used for the PSS-
HN, whereby a ±0.5 standard deviation difference (i.e. 12.8 points)
indicated a clinically relevant difference [29,30].
Statistics
Differences between the groups were calculated at every time point.
Independent t-tests were performed to find any statistical significant
differences between the two treatment groups for each symptom or
functioning scale. For HRQoL during treatment compared with baseline
(both groups) no statistical tests were performed and therefore results
are descriptive. As described above, for all the separate questionnaires,
we have not only reported statistical significant differences, but also
(minimal) clinically important differences, because statistical sig-
nificance does not provide information about clinical meaningfulness
i.e. whether the observed effect is larger than the smallest clinically
important effect [31,32].
The change in HRQoL and symptom burden (separate models for
each scale) by treatment group was analyzed using linear mixed-effects
models (i.e. covariance pattern model with an unstructured error var-
iance matrix and maximum likelihood estimation) [33]. This technique
uses data efficiently by including incomplete cases in the analysis. As a
result, bias is limited and statistical power is preserved. Time was
analyzed as a regular categorical predictor with four levels (i.e. four
time points). The interaction of treatment group and time was tested
separately. Analyses were performed in IBM SPSS 22.0 with a sig-
nificance level of α=0.05.
Results
Patients
A total of 106 patients were included from six centres between
January 2012 and July 2015. At randomization, 48 patients were al-
located to standard group and 47 patients to the prophylaxis group.
Nine included patients could not be randomized (e.g. due to the use of
antibiotics 14 days prior to randomization). Both groups were well
balanced with respect to baseline clinical and sociodemographic char-
acteristics (Table 1).
HRQoL completion rate and baseline scores
Only patients who completed the questionnaires at baseline as well
as at follow up were included in analyses (complete case analysis).
Therefore, a total of 34 patients in the standard group (70.8%) and 28
patients in the prophylaxis group (59.6%) were included in final
Table 2
Baseline scores in HRQoL measured by the EORTC QLQ-C30 and QLQ-H&N35.
(N) after each subscales means the number of available questionnaires.
Baseline
EORTC
stage III-
IV
(mean)₣
Standard
group
(n=34)
Prophylaxis
group
(n=28)
Δ p
PSS-HN
Normalcy of diet
(N)
NA 77.5 (32) 68.8 (25) −8.7 0.253
Eating in public(N) NA 93.8 (32) 84.0 (25) −9.8 0.126
Understandability
of speech(N)
NA 89.8 (32) 90.0 (25) 0.2 0.977
QLQ-C30
Physical functioning
(N)
81.2 89.4 (34) 89.0 (28) −0.4 0.895
Role functioning(N) 78.8 74.0 (34) 79.8 (28) 5.8 0.413
Emotional
functioning(N)
71.2 77.7 (34) 82.1 (28) 4.4 0.382
Cognitive
functioning(N)
86.4 89.7 (34) 94.0 (28) 4.3* 0.267
Social functioning
(N)
82.2 79.4 (34) 88.7 (28) 9.3* 0.104
Global health status
(N)
63.1 72.2 (33) 72.0 (28) −0.2 0.968
Fatigue(N) 27.6 16.7 (34) 21.0 (28) 4.3 0.415
Nausea/vomiting
(N)
5.2 0.5 (33) 5.4 (28) 4.9* 0.075
Pain(N) 24.9 18.1 (34) 18.5 (28) 0.4 0.962
Dyspnoea(N) 18.0 8.8 (34) 6.0 (28) −2.8 0.548
Insomnia(N) 28.5 27.5 (34) 23.8 (28) −3.7 0.629
Appetite loss(N) 19.4 10.8 (34) 19.0 (28) 8.2 0.230
Constipation(N) 11.7 12.7 (34) 10.7 (28) −2 0.719
Diarrhea(N) 6.1 1.0 (34) 6.0 (28) 5* 0.068
Financial problems
(N)
18.8 18.6 (34) 11.9 (28) −6.7* 0.289
QLQ-H&N35a
Pain(N) NA 18.8 (34) 25.3 (27) 6.5 0.203
Swallowing(N) NA 16.3 (34) 28.7 (27) 12.4† 0.024‡
Senses problems(N) NA 16.2 (34) 7.4 (27) −8.8 0.090
Speech problems(N) NA 16.5 (33) 14.0 (27) −2.5 0.643
Social eating(N) NA 13.1 (33) 24.4 (26) 11.3† 0.027‡
Social contact(N) NA 4.0 (33) 7.7 (27) 3.7 0.302
Sexuality(N) NA 20.6 (30) 13.8 (23) −6.8 0.428
Teeth(N) NA 13.7 (34) 14.7 (25) 1 0.891
Opening mouth(N) NA 26.5 (34) 24.4 (26) −2.1 0.800
Dry mouth(N) NA 17.6 (34) 18.5 (27) 0.9 0.886
Sticky saliva(N) NA 21.6 (34) 20.5 (26) −1.1 0.887
Coughing(N) NA 24.5 (34) 22.2 (27) −2.3 0.704
Felt ill(N) NA 6.9 (33) 6.2 (26) −0.7 0.890
Pain killers(N) NA 48.5 (33) 37.0 (27) −11.5† 0.110
Nutritional
supplements(N)
NA 27.3 (33) 37.0 (27) 9.7 0.427
Feeding tube(N) NA 9.1 (33) 7.7 (26) −1.4 0.851
NA=not available.
* Small clinically important difference.
† Clinically relevant difference of more than 10 points.
‡ Statistically significant.
₣ EORTC reference data from patients with stage III or IV head and neck
cancer [32].
a Weight gain and weight loss not reported due to difficult interpretation.
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analyses. At baseline 34 patients in the standard group and 28 patients
in the prophylaxis group completed the questionnaires, before the start
of prophylactic antibiotics (at day 28) 34 and 26 patients respectively,
at the end of radiotherapy 25 and 19 patients and at the end of follow
up 34 and 28 patients respectively. However, this could be different
patients who completed the questionnaires at any time point.
At baseline, we found small clinically relevant differences between
the two treatment arms in some of the EORTC QLQ-C30 scales.
However, none of these were statistically significant.
Three items on the EORTC-HN35 were clinically relevant different
with a difference of more than 10 points. The prophylaxis group scored
higher on ‘swallowing’ (28.7 vs. 16.3) and ‘social eating’ (24.2 vs. 13.1)
than the standard group and lower on ‘painkillers’ (37.0 vs. 48.5) than
the standard group. However, only the differences on ‘swallowing’
(p= 0.024) and ‘social eating’ (p= 0.027) were statistically significant
in favour of the standard group (Table 2).
The scores on the EORTC QLQ-C30 were comparable with EORTC
reference data from patients with stage III or IV head and neck cancer
[34].
HRQoL between treatment groups during treatment
At day 28 of chemotherapy, before the start of prophylactic anti-
biotics, there was no statistically significant difference between the
standard and prophylaxis group (Table 3).
After radiotherapy, at which point the prophylaxis group were still
taking antibiotics and acute toxicities of treatment are generally the
highest, the prophylaxis group reported fewer symptoms on almost all
subscales of the QLQ-C30, QLQ-H&N35 and PS-HN, though almost no
items were significantly different to the 0.05 level (Table 3). ‘Cognitive
functioning’ and ‘social functioning’ from the EORTC QLQ-C30 and
‘social contact’ from the QLQ-H&N35 were significantly different in
favour of the prophylaxis group (Fig. 1).
At 3.5months after the end of chemoradiotherapy, the standard
group scored lower on ‘social eating’ (17.6 vs. 34.3, p= 0.017) and
‘teeth’ (10.1 vs. 26.9, p= 0.019) to a strong clinically relevant level
compared to the prophylaxis group in favour of the standard group
(Table 3).
HRQoL during treatment compared with baseline in both groups
The standard group had a lower score to a clinically relevant level
on all functional subscales of the EORTC-QLQ-C30, except for ‘emo-
tional functioning,’ at the end of radiotherapy compared to baseline,
while the prophylaxis group had a lower score to a clinically relevant
level only on ‘role functioning’ and ‘global QoL’ (Fig. 1). Scores on all
functional subscales returned to baseline values at 3.5 months follow up
for both treatment groups. In both groups, patients experiences a
clinically relevant increase in symptoms after chemoradiotherapy
compared to baseline that persisted until 3.5months follow up on the
items ‘senses problems’, dry mouth’, ‘sticky saliva’, and ‘feeding tube’
(Table 3). On the other symptom subscales of the EORTC QLQ-C30 and
QLQ-H&N35, there was a clinically meaningful increase in scores
during chemoradiotherapy measured at day 28 and at the end of
radiotherapy compared with baseline, which recovered to baseline le-
vels at 3.5 months follow up for both groups (Table 3).
Course of HRQoL
At a group level, the EORTC QLQ-C30 functioning scales ‘physical
functioning’, ‘role functioning’, and ‘global QoL’ significantly decreased
between baseline and the end of chemoradiotherapy, indicating pro-
blems increased by the end of chemoradiotherapy. These changes were
similar in both treatment groups (Table 4). Patients scored statistically
significantly higher on ‘fatigue’, ‘pain’, ‘constipation’, and ‘diarrhea’ of
the EORTC QLQ-C30 at the end of radiotherapy compared to baselineTa
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and 3.5months follow-up, with no difference between the two treat-
ment groups. Patients also scored significantly higher on ‘Nausea and
vomiting’ at the end of radiotherapy compared with all other time-
points. The symptoms of the EORTC QLQ-H&N35 ‘pain’, ‘swallowing’,
‘sticky saliva’, changed significantly between the end of radiotherapy
and baseline and end of radiotherapy and end of follow-up, with sig-
nificantly higher scores at the end of radiotherapy. The symptoms
‘senses problems’, ‘speech problems’, ‘social eating’, ‘sexuality’, ‘dry
mouth’, ‘coughing’, ‘felt ill’ and the need of ‘a feeding tube’ scores all
significantly higher at the end of radiotherapy compared with baseline.
On the ‘cognitive functioning’ and ‘social functioning’ scales of the
EORTC QLQ-C30 and the ‘social contact’ and ‘feeling ill’ symptom
scales of the EORTC QLQ-H&N35 the standard group experienced sig-
nificantly more problems over time compared to the prophylaxis group
(Table 4).
Discussion
HRQoL was an important secondary objective of the PANTAP-study,
which showed that prophylactic administration of amoxicillin/clavu-
lanic acid reduced the number of hospital admissions, episodes of fever
and healthcare costs without lowering the incidence of pneumonias.
This study showed that prophylactic antibiotics also seemed to improve
most aspects of HRQoL at the end of radiotherapy compared to standard
care alone, although not all subscales were statistically significantly
different.
At baseline some small clinically relevant differences were found
between the two treatment groups, though most disappeared before the
start of the prophylactic antibiotics at day 28. However, at the end of
radiotherapy, when patients in the prophylaxis group were still taking
the prophylactic antibiotics, the prophylaxis group reported a better
HRQoL on most items compared to the standard group. At the end of
follow up, 3.5months after the end of chemoradiotherapy, few differ-
ences still existed between the two treatment groups. This suggests the
advantage of the prophylaxis, with respect to the HRQoL, is experi-
enced between the start of the antibiotics and the end of radiotherapy,
as seen in the decreased decline in functional subscales. During the
study, HRQoL deteriorated from baseline to day 28 and the end of
radiotherapy; patients experienced a significantly higher symptom
burden at the end of radiotherapy compared to baseline on 10 of the 18
symptoms covered by the EORTC QLQ-H&N35 reflects the high level of
toxicity at the end of chemoradiotherapy. This confirms findings in the
literature that show a decline in HRQoL during and at the end of
(chemo)radiotherapy [9,11]. This deterioration can be explained by
treatment toxicities.
Interestingly, we observed no difference in reported levels of diar-
rhoea in the prophylaxis group compared to the standard group. This is
surprising given the relatively long use of antibiotics in the prophylaxis
group.
At follow-up, 3.5months after the end of chemoradiotherapy, most
subscales returned to baseline-values or better, which has been pre-
viously described in other studies [4,9,12]. Only the ‘senses problems’,
‘dry mouth’, and ‘sticky saliva’ symptom scales saw no improvement at
follow up. This is also agrees with previous studies by Vergeer et al. and
Jellema et al. that showed dry mouth, sticky saliva and diminished taste
can be long lasting or even permanent [10,35], due to permanent da-
mage to the salivary glands caused by the radiotherapy. The fact that
patients in the prophylaxis group scored significantly higher on the
subscales ‘social eating’ and ‘teeth’ at follow-up, cannot be explained by
the use of prophylactic antibiotics. This may be due to statistical issues
related to the small number of completed questionnaires.
Slightly more patients included in the prophylaxis group had hy-
popharyngeal cancer, although not statistically different.
Hypopharyngeal cancer is associated with a greater risk of aspiration
and pneumonia. This may have influenced the number of aspiration
pneumonias in both groups. But as the number of pneumonias were not
different between the two groups, it likely would not have had any
consequence on the HRQoL outcomes.
To the best of our knowledge, the PANTAP study is the first study to
investigate the effect of prophylactic antibiotics on the occurrence of
pneumonias, the number of hospital admissions and healthcare costs in
LAHNC patients treated with chemoradiotherapy. The strength of the
Fig. 1. On the top three functional items of the QLQ-C30 showing a decrease during chemoradiotherapy, and an increase at follow up, whereas the prophylaxis group
in general had a less steeper decline after radiotherapy compared with the standard group. On the bottom three symptom subscales, showing an increase in symptoms
during radiotherapy, with improvement of symptoms at follow up, except for some specific subscales like dry mouth. The prophylaxis group felt less ill during
chemoradiotherapy.
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current study is the focus on the effect of prophylactic antibiotics on
HRQoL in this patient group. As far as we know, only one other study
has looked at the effect of antibiotics on HRQoL. Braimah et al. in-
vestigated the effect of oral antibiotics on HRQoL after mandibular
third molar surgery and showed that extended oral use of amoxicillin/
clavulanic acid was correlated with a better, though not statistically
significant, HRQoL [36].
A limitation of this study is the relative low compliance of com-
pleted HRQoL questionnaires, particularly at the end of radiotherapy.
In addition, fewer questionnaires were completed by the prophylaxis
group (at baseline 70.8% versus 59.6% for standard versus prophylaxis
groups, respectively). Because of this, the number of included ques-
tionnaires was too low to perform multivariate analyses and no con-
clusions could be drawn on the impact of pneumonia or hospital ad-
mission on HRQoL. The explorative nature of this study also made it
impossible to correct for multiple comparisons or confounders such as
comorbidity. Furthermore, the last follow-up questionnaire was at
3.5 months after the end of chemoradiotherapy, limiting our ability to
assess the long-term effects of prophylactic antibiotics on HRQoL.
However, as HRQoL largely returned to baseline values at 3.5 months
follow up with almost no differences between the groups, no large
clinically relevant differences would be expected in future.
In conclusion, prophylactic antibiotics in LAHNC patients treated
with chemoradiotherapy may mitigate deterioration of HRQoL at the
end of the radiotherapy compared to standard care alone. However, no
differences were found between groups at the end of follow up. This
study should be replicated with larger numbers and more potential
covariates. However, given the fact that prophylactic antibiotics,
compared to standard treatment, reduced the number of hospital ad-
missions and costs and also seemed to help maintain HRQoL at the end
of the chemoradiotherapy, prophylactic antibiotics in this patients
group can be considered.
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